Latent reservoirs of HIV: obstacles to the eradication of virus
about
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studiesThe distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses.Gene therapy strategies for HIV/AIDS: preclinical modeling in humanized miceA binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytesPre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradicationHIV-AIDS: much accomplished, much to do.Correlation of acute humoral response with brain virus burden and survival time in pig-tailed macaques infected with the neurovirulent simian immunodeficiency virus SIVsmmFGbAnti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor.Identifying the membrane proteome of HIV-1 latently infected cells.Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1.Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy.Targeting TNF and TNF Receptor Pathway in HIV-1 Infection: from Immune Activation to Viral ReservoirsViral decay kinetics in the highly active antiretroviral therapy-treated rhesus macaque model of AIDS.Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDSPreferential feline immunodeficiency virus (FIV) infection of CD4+ CD25+ T-regulatory cells correlates both with surface expression of CXCR4 and activation of FIV long terminal repeat binding cellular transcriptional factorsEnhanced antiretroviral therapy in rhesus macaques improves RT-SHIV viral decay kineticsSuccessful targeting and disruption of an integrated reporter lentivirus using the engineered homing endonuclease Y2 I-AniI.Induction of cell death in human immunodeficiency virus-infected macrophages and resting memory CD4 T cells by TRAIL/Apo2lKinetics of human immunodeficiency virus type 1 (HIV) DNA integration in acutely infected cells as determined using a novel assay for detection of integrated HIV DNA.Induction of TAK (cyclin T1/P-TEFb) in purified resting CD4(+) T lymphocytes by combination of cytokines.The infiltration kinetics of simian immunodeficiency virus-specific T cells drawn to sites of high antigenic stimulation determines local in vivo viral escape.Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapyImpact of short-term combined antiretroviral therapy on brain virus burden in simian immunodeficiency virus-infected and CD8+ lymphocyte-depleted rhesus macaques.HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir.Combination of biological screening in a cellular model of viral latency and virtual screening identifies novel compounds that reactivate HIV-1Capsid is a dominant determinant of retrovirus infectivity in nondividing cells.Rational design of drugs that induce human immunodeficiency virus replication.Macrophages and their relevance in Human Immunodeficiency Virus Type I infection.Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA loadBasic quinolinonyl diketo acid derivatives as inhibitors of HIV integrase and their activity against RNase H function of reverse transcriptase.Pathogenesis and treatment of HIV infection: the cellular, the immune system and the neuroendocrine systems perspective.Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study.Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals.Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy.Susceptibilities of simian immunodeficiency virus to protease inhibitorsR5 and X4 HIV envelopes induce distinct gene expression profiles in primary peripheral blood mononuclear cells.Evolutionary indicators of human immunodeficiency virus type 1 reservoirs and compartmentsHIV reproducibly establishes a latent infection after acute infection of T cells in vitro.HIV Eradication: Progress and Challenges
P2860
Q24656950-C1568FB7-E9CC-489F-A8FA-6EC86C63591DQ25257032-DF6F031F-5A16-4D6A-AB1B-45D5506BFCCAQ27022347-4F5CFB74-74E1-4CA5-B7B0-F1B1A4921162Q28344177-A738D555-4BBE-42D0-BD9D-B1F06FAE795AQ28486204-AEB91A75-5213-4799-AE21-DAF1861081FDQ28731318-21EF84A8-39A6-48AD-BE94-0AAB02522EB0Q30354779-A45A9B2F-4B82-4FDD-A545-74C0BD6453ABQ30478136-ED4E58C4-86ED-4D7D-81C6-03E8540FB980Q33223969-12213975-4683-47E2-8241-683F989BDB73Q33269741-1E4F6C3A-9D81-4A4D-8664-927F0D76BC9BQ33326800-10D1E283-46A0-4B44-987D-446177AD157AQ33510903-9E931611-D75B-486F-B245-D2FD3A5A88F2Q33613493-648D9981-2E83-43B5-899E-50BA919D179EQ33644248-EFF1CE17-7A96-4BCC-9697-05E00E69F728Q33676630-0AE3546B-AAE6-4DA8-87E5-5026D5AE26C4Q33724212-A77F5287-5200-40D5-AA08-8E964DBD51F3Q33798207-9D0D78A1-BC46-433E-83CF-3DEB8ABFFC2AQ33844698-72123536-113C-475A-BFB7-43811D9255B8Q33849293-047C9E33-1D67-41D5-83CA-B7213E98744CQ33849497-115C6EFC-0AE0-4AB7-93AA-DF9DE82B3F58Q33849629-E80235ED-4928-4058-84F0-89BF742DE5A9Q33949260-188A91B5-5FE3-4EA0-9265-36AD78613DA0Q33962223-297FE8F7-E8EE-443C-AFE2-AAC6F5A77C33Q34033558-8EC82DE0-1E6B-42E4-82E0-3803D6AB3101Q34097573-70505451-B492-456D-97F6-6C9CF3FB9FCEQ34132738-59115056-A0FD-4DFC-BCC1-56A272DF1324Q34152408-3F5A9A4C-9545-4091-9F55-D7250D3F8B62Q34229958-4533DDFA-A66F-44CA-A066-37FE60AF1E6AQ34303855-85BB9105-CD69-41AF-9C25-ADB56F0E6864Q34348055-F74E4CB8-D07A-47B7-8913-63E75EFC35EFQ34372481-0B91387C-1CBE-45BE-8E74-488F4903D636Q34650866-BBCF9AEB-DC3C-4D35-AA06-635C560C83B4Q34713877-4239406F-890B-415A-9E68-9A3446644368Q34762506-FC7E1848-D4DF-4576-8116-ED245317CA1BQ34789249-E4A7A418-D21B-4340-A86A-256D3301A5D2Q34939250-5F6EC411-0F34-4BF0-8401-558446913F82Q34944066-BBF6B878-9B24-4D29-8507-D3657226444BQ34975321-03F3667B-0DAF-4F53-89F6-6AA015E6ED46Q34985945-99A9E381-9263-41BD-AD7C-A7021C9FB21AQ35050149-DACAD063-679A-4750-BB53-8C216779DFFF
P2860
Latent reservoirs of HIV: obstacles to the eradication of virus
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Latent reservoirs of HIV: obstacles to the eradication of virus
@ast
Latent reservoirs of HIV: obstacles to the eradication of virus
@en
Latent reservoirs of HIV: obstacles to the eradication of virus
@nl
type
label
Latent reservoirs of HIV: obstacles to the eradication of virus
@ast
Latent reservoirs of HIV: obstacles to the eradication of virus
@en
Latent reservoirs of HIV: obstacles to the eradication of virus
@nl
prefLabel
Latent reservoirs of HIV: obstacles to the eradication of virus
@ast
Latent reservoirs of HIV: obstacles to the eradication of virus
@en
Latent reservoirs of HIV: obstacles to the eradication of virus
@nl
P2860
P356
P1476
Latent reservoirs of HIV: obstacles to the eradication of virus
@en
P2093
P2860
P304
P356
10.1073/PNAS.96.20.10958
P407
P577
1999-09-28T00:00:00Z